Summary
The excretion of radioisotope following the administration of three specifically14C-labelled forms of streptozotocin was investigated in the rat using ureter and bile duct cannulation techniques. The urine collected during the first hour following the administration of the drug contained the highest proportion of injected radioactivity (approximately 34% with (3′-methyl-14C)-streptozotocin and approximately 40% each with (1-14C)- and (2′-14C)-streptozotocin. Over the entire experimental period (6 hours), approximately 70% of the injected radioactivity of (1-14C)- and (2′-14C)-streptozotocin appeared in the urine. With (3′-methyl-14C)-streptozotocin, only 53% of the injected radioactivity appeared in the urine over the same period. In contrast to the high urinary excretion, less than 3 % of the injected radioactivity from all three radiolabelled streptozotocin samples appeared in the bile. The in vivo and in vitro metabolism of streptozotocin was also investigated. In addition to substantial amounts of unchanged drug, three radiolabelled metabolites (two major and one minor) were detected in the urine during the 6 hour collection period following the administration of (1-14C)- and (2′-14C)-streptozotocin. In contrast, only unchanged (3′-methyl-14C)-streptozotocin was detected in the urine collected over the same period following the administration of the methyl labelled drug. The two major metabolites were also produced when (1-14C)- and (2′-14C)-streptozotocin were incubated with a rat liver supernatant fraction (100,000 X g). The liver was further demonstrated to be the major site of metabolism in isolated liver perfusion studies in which both (1-14C)- and (2′-14C)-streptozotocin were quantitatively converted to the two major metabolites. The two major metabolites of (1-14C)-streptozotocin, whether produced in vivo or in vitro, were chromatographically homogeneous with the two major metabolites formed from (2′-14C)-streptozotocin. Nicotinamide pretreatment had no apparent effect on the urinary excretion of streptozotocin and its metabolites.
Article PDF
Similar content being viewed by others
Avoid common mistakes on your manuscript.
References
Karunanayake, E. H., Hearse, D. J., Mellows, G.: The synthesis of14C-streptozotocin and its distribution and excretion in the rat. Biochem. J.142, 673–683 (1974a)
Hems, R., Ross, B. D., Berry, M. N., Krebs, H. A.: Gluconeogenesis in the perfused rat liver. Biochem. J.101, 284–292 (1966)
Karunanayake, E. H., Hearse, D. J., Mellows, G.: The distribution and excretion of (14C)-streptozotocin in the rat. Biochem. Soc. Trans.2, 1006–1009 (1974b)
Karunanayake, E. H., Baker, J. R. J., Christian, R. A., Hearse, D. J., Mellows, G.: Autoradiographic study of the distribution and cellular uptake of (14C)-streptozotocin in the rat. Diabetologia12, 1–6 (1976)
Milburn, P., Smith, R. L., Williams, R. T.: Biliary excretion of foreign compounds. Biochem. J.105, 1275–1281 (1967a)
Milburn, P., Smith, R. L., Williams, R. T.: Biliary excretion of foreign compounds. Biochem. J.105, 1283–1287 (1967b)
Dulin, W. E., Wyse, B. M.: Studies on the ability of compounds to block the diabetogenic action of streptozotocin. Diabetes18, 459–466 (1969)
Karunanayake, E. H., Hearse, D. J., Mellows, G.: The metabolic fate and elimination of streptozotocin. Biochem. Soc. Trans.3, 410–414 (1975a)
Lawley, P. D., Shah, S. A.: N-methyl-N-nitrosourea and N-methyl-N1-nitro-N-nitrosoguanadine. Biochem. J.128, 117–132 (1972)
Rakienten, N., Rakienten, M. L., Nadkarni, M. V.: Studies on the diabetogenic action of streptozotocin. Cancer Chemother. Rep.29, 91–98 (1963)
Schein, P. S., Cooney, D. A., McMenamin, M. G., Anderson, T.: Streptozotocin diabetes — further studies on the mechanisms of depression of nicotinamide adenine dinucleotide concentrations in mouse pancreatic islets and liver. Biochem. Pharmcol.22, 2625–2631 (1973)
Schein, P. S., Loftus, S.: Streptozotocin: Depression of mouse liver pyridine nucleotides. Cancer Res.28, 1501–1506 (1968)
Hinz, M., Katsilambros, N., Maier, V., Schatz, H., Pfeiffer, E. F.: Significance of streptozotocin induced nicotinamide adenine-dinucleotide (NAD) degradation in mouse pancreatic islets. FEBS Letters30, 225–228 (1973)
Dean, P. M., Mathews, E. K.: The bioelectric properties of pancreatic islets cells: Effect of diabetogenic agents. Diabetologia8, 173–178 (1972)
Petrack, B., Greengard, P., Kalinsky, H.: On the relative efficacy of nicotinamide and nicotinic acid as precursors of nicotinamide adenine dinucleotide. J. biol. Chem.241, 2367–2372 (1966)
Collins, P. B., Chaykin, S.: The management of nicotinamide and nicotinic acid in the mouse. J. biol. Chem.247, 778–783 (1972)
Karunanayake, E. H., Baker, J. R. J., Christian, R., Hearse, D. J., Mellows, G.: Microradioautographic study of the distribution and uptake of (14C)-streptozotocin in rat tissues. Biochem. Soc. Trans.3, 414–417 (1975b)
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Karunanayake, E.H., Hearse, D.J. & Mellows, G. Streptozotocin: Its excretion and metabolism in the rat. Diabetologia 12, 483–488 (1976). https://doi.org/10.1007/BF01219512
Received:
Revised:
Issue Date:
DOI: https://doi.org/10.1007/BF01219512